Analysts Set Expectations for TCRX Q1 Earnings

TScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) - Stock analysts at Wedbush issued their Q1 2026 EPS estimates for shares of TScan Therapeutics in a note issued to investors on Tuesday, May 6th. Wedbush analyst D. Nierengarten expects that the company will earn ($0.23) per share for the quarter. Wedbush currently has a "Outperform" rating and a $7.00 target price on the stock. The consensus estimate for TScan Therapeutics' current full-year earnings is ($1.12) per share. Wedbush also issued estimates for TScan Therapeutics' Q2 2026 earnings at ($0.24) EPS, Q3 2026 earnings at ($0.25) EPS and Q4 2026 earnings at ($0.22) EPS.

A number of other brokerages also recently commented on TCRX. Barclays decreased their price objective on shares of TScan Therapeutics from $14.00 to $3.00 and set an "overweight" rating for the company in a research report on Friday, March 7th. HC Wainwright decreased their price objective on TScan Therapeutics from $15.00 to $10.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. Morgan Stanley reissued an "overweight" rating and issued a $10.00 target price on shares of TScan Therapeutics in a research report on Friday, March 14th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $9.00 price objective on shares of TScan Therapeutics in a research note on Tuesday, April 8th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $8.50.

TScan Therapeutics Stock Down 3.6%

Shares of NASDAQ:TCRX traded down $0.05 during midday trading on Thursday, hitting $1.32. The stock had a trading volume of 114,625 shares, compared to its average volume of 361,356. The company has a quick ratio of 9.56, a current ratio of 9.56 and a debt-to-equity ratio of 0.13. The business's 50-day simple moving average is $1.48 and its 200-day simple moving average is $2.66. TScan Therapeutics has a 12 month low of $1.02 and a 12 month high of $9.69. The company has a market cap of $74.70 million, a P/E ratio of -1.25 and a beta of 1.06.

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.26) earnings per share for the quarter, beating analysts' consensus estimates of ($0.28) by $0.02. TScan Therapeutics had a negative return on equity of 58.72% and a negative net margin of 1,188.88%. The firm had revenue of $2.17 million during the quarter, compared to the consensus estimate of $1.62 million.

Institutional Investors Weigh In On TScan Therapeutics

Several hedge funds have recently made changes to their positions in the company. Lynx1 Capital Management LP boosted its holdings in shares of TScan Therapeutics by 2.5% in the fourth quarter. Lynx1 Capital Management LP now owns 5,357,347 shares of the company's stock worth $16,286,000 after buying an additional 132,747 shares during the last quarter. Aberdeen Group plc boosted its stake in shares of TScan Therapeutics by 0.9% during the first quarter. Aberdeen Group plc now owns 891,448 shares of the company's stock valued at $1,230,000 after purchasing an additional 7,744 shares during the period. abrdn plc raised its position in TScan Therapeutics by 137.8% during the 4th quarter. abrdn plc now owns 883,704 shares of the company's stock valued at $2,686,000 after purchasing an additional 512,049 shares in the last quarter. Dimensional Fund Advisors LP raised its position in shares of TScan Therapeutics by 108.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 280,028 shares of the company's stock worth $851,000 after acquiring an additional 145,731 shares in the last quarter. Finally, Tocqueville Asset Management L.P. grew its stake in TScan Therapeutics by 26.8% during the 4th quarter. Tocqueville Asset Management L.P. now owns 260,870 shares of the company's stock worth $793,000 after buying an additional 55,140 shares during the last quarter. 82.83% of the stock is currently owned by institutional investors.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.